TNFRSF8 and primary cutaneous T-cell non-Hodgkin lymphoma: Additionally, as for PTCL, data on response to brentuximab vedotin in patients with low or no CD30 expression are also required to determine the optimal role of brentuximab vedotin across CTCL subtypes.